Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 4, 2008 - Issue 4
Submit an article Journal homepage
226
Views
7
CrossRef citations to date
0
Altmetric
Drug Evaluation

Telmisartan in the treatment of hypertension

Barbara H Rosario Sheffield Teaching Hospitals NHS Foundation Trust, Department of Geriatric Medicine, Sir Robert Hadfield Wing, Northern General Hospital, Herries Road, Sheffield S5 7AU, UK +44 0114 271 4971; +44 0114 271 5981; [email protected]
, MRCP(UK) &
Timothy James Hendra Sheffield Teaching Hospitals NHS Foundation Trust, Department of Geriatric Medicine, Sir Robert Hadfield Wing, Northern General Hospital, Herries Road, Sheffield S5 7AU, UK +44 0114 271 4971; +44 0114 271 5981; [email protected]
, BSc(Hons) MD FRCP
Pages 485-492 | Published online: 23 Apr 2008

Bibliography

  • Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87
  • Gosse P, Neutel JM, Schumacher H, et al. The effect of telmisartan and ramipril on early morning blood pressure surge: a pooled analysis of two randomized clinical trials. Pooled analysis of PRISMA I and II trials. Blood Press Monit 2007;12:141-7
  • Kario K, Pickering TG, Umeda Y, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003;107:1401-6
  • Boehringer Ingelheim. Micardis, summary of product characteristics. In: Boehringer Ingelheim International GmbH; May 2006
  • Kjeldsen SE, Julius S. Hypertension mega-trials with cardiovascular end points: Effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Am Heart J 2004;148:747-54
  • Dzau VJ. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001;37:1047-52
  • Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation 2006;114:838-54
  • Barnett AH. Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study. Acta Diabetol 2005;42:S42-9
  • Giles TD. A perspective on telmisartan and cardiovascular risk. Rev Cardiovasc Med 2007;8:154-9
  • Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906
  • Sokol SI, Portnay EL, Curtis JP, Nelson MA, et al. Modulation of the renin-angiotensin-aldosterone system for the secondary prevention of stroke. Neurology 2004;63:208-13
  • Yusuf S, Sleight P, Pogue J, Bosch J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53
  • Dahlof B, Devereaux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003
  • Papademetriou V, Farsang C, Elmfeldt D, et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol 2004;44:1175-80
  • Sharma AM. Telmisartan: hypertension, the ACE of ARBs? Hypertension 2006;47:822
  • Neutel JM, Smith DHG. Dose response and antihypertensive efficacy of the AT1 receptor antagonist telmisartan in patients with mild to moderate hypertension. Adv Ther 1998;15:206-17
  • Boehringer Ingelheim Pharma. Drug prescribing information: Micardis; 1998
  • Stangier J, Schmid J, Turck D, et al. Absorption, metabolism and excretion of intravenously and orally administered [14C]telmisartan in health volunteers. J Clin Pharmacol 2000;40:1312-22
  • Tatami S, Sarashina A, Yamamura N, et al. Population pharmacokinetics of an angiotensin II receptor antagonist, telmisartan, in healthy volunteers and hypertensive patients. Drug Metab Pharmacokin 2003;18:203-11
  • Thomas GN, Chan P, Tomlinson B. The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension. Drugs Aging 2006;23:131-55
  • Smith DHG, Matzek K, Kempthorne-Rawson J. Dose response and safety of telmisartan in patients with mild to moderate hypertension. J Clin Pharmacol 2000;40:1380-90
  • Williams B, Gosse P, Lowe L,, et al. The prospective, randomised investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I). J Hypertens 2006;24:193-200
  • Lacourciere Y, Neutel JM, Davaidal G, et al. A multicentre, 14 week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. Am J Hypertens 2006;19:104-12
  • Lacourciere Y, Lenis J, Orchard R, et al. A comparison of the efficacies and duration of action of the angiotensin II receptor blocker telmisartan to amlodipine. Blood Press Monit 1998;3:295-302
  • Mallion JM, Siche JP, Lacourciere Y, Telmisartan Blood Pressure Monitoring Group. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens 1999;13:657-64
  • Littlejohn T, Mroczek W, Marbury T, et al. A prospective, randomized, open-label trial comparing telmisartan 80mg with valsartan 80mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. Can J Cardiol 2000;16:1123-32
  • Smith DHG, Cramer M-JM, Neutel JM, et al. Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies. Blood Press Monit 2003;8:111-7
  • White WB, Lacourciere Y, Davidal G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. Am J Hypertens 2004;17:347-53
  • Calvo C, Hermida RC, Ayala DE, Ruilope LM. Effects of telmisartan 80mg and valsartan 160mg on ambulatory blood pressure in patients with essential hypertension. J Hypertens 2004;22:837-46
  • Neutel J, Littlejohn TW, Chrysant SG, Singh A. Telmisartan/hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild-to-moderate hypertension. Hypertens Res 2005;28:555-63
  • Lacourciere Y, Neutel JM, Schuchacher H. Comparison of fixed -dose combinations of telmisartan/hydrochlorthiazide 40/12.5mg and 80/12.5mg and a fixed-dose combination of losartan/hydrochlorthiazide 50/12.5mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized open-label, blinded-end point (PROBE) trials. Clin Ther 2005;27:1795-805
  • White WB, Punzi HA, Murwin D, et al. Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorthiazide 25mg once daily for the treatment of hypertension J Clin Hypertens (Greenwich) 2006;8:626-33
  • Sharma AM, Davidson J, Koval S, Lacourciere Y. Telmisartan/hydrochlorthiazide versus valsartan/hydrochlorthiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study. Cardiovasc Diabetol 2007;6:28
  • Sharma AM, Davidson JA, Gavin Jr III, Desousa NJ. Antihypertensive efficacy of telmisartan/hydrocblorothiazide versus valsartan/hydrochlorothiazide in high-risk overweight/obese patients with hypertension and type 2 diabetes: the SMOOTH study. Diabetes 2006;55(Suppl 1):A73
  • Manolis AJ, Reid JL, Zeeuw D, et al.; Aramis Study Group. Angiotensin II receptor antagonist telmisartan in isolated systolic hypertension (ARAMIS) study: efficacy and safety of telmisartan 20, 40 or 80 mg versus hydrochlorothiazide 12.5 mg or placebo. J Hypertens 2004;22:1033-7
  • Neldham S, Edwards C; Athos Study Group. Telmisartan plus HCTZ vs. amlodipine plus HCTZ in older patients with systolic hypertension: results from a large ambulatory blood pressure monitoring study. Am J Geriatr Cardiol 2006;15:151-60
  • Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet 2007;370:591-603
  • Schmeider RE. Endothelial dysfunction: how can one intervene at the beginning of the cardiovascular continuum? J Hypertens Suppl 2006;24:S31-5
  • Galle J, Bravo SQ, Wanner C. Antiproteinuric effects of telmisartan versus valsartan in patients with Type 2 diabetes and overt nephropathy. J Hypertens 2006;24(Suppl 6):S342
  • Schmeider RE, Delles C, Mimran A, et al. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care 2007;30:1351-6
  • Vogt L, Navis G, Koster J, et al. The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomised, double-blind, placebo-controlled trial. J Hypertens 2005;23:2055-61
  • Fogari R, Derosa G, Zoppi A, et al. Effect of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. Am J Hypertens 2007;20:417-22
  • Costa FV. Telmisartan: standing out in a crowded contest? High Blood Press Cardiovasc Prev 2006;13:85-94
  • Derosa G, Ragonesi PD, Mugellini A, et al. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res 2004;27:457-64
  • Derosa G, Fogari E, D'Angelo A, et al. Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. J Clin Pharm Ther 2007;32:261-8
  • Derosa G, Cicero AF, Bertone G, et al. Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study. Clin Ther 2004;26:1228-36
  • Savelieva I, Camm J. Is there any hope for angiotensin-converting enzyme inhibitors in atrial fibrillation? Am Heart J 2007;154:403-6
  • British Medical Association and Royal Pharmaceutical Society of Great Britain. BNF54: British National Formulary (BNF); 2007
  • Phillips C, Kashani A, Ko DK, et al. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantative review of data from randomised clinical trials. Arch Intern Med 2007;167:1930-6
  • Tsuyuki R, McDonald MA. Angiotensin receptor blockers do not increase risk of myocardial infarction. Circulation 2006;114:855-60
  • Schrader J, Luders S, Kulschewski A, et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomised controlled study (MOSES). Stroke 2005;36:1218-26
  • Mochizuki S, Dahof B, Shimizu M, et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (JIKEI Heart Study): a randomised open-label, blinded endpoint morbidity-mortality study. Lancet 2007;369:1413-9
  • Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31
  • Teo K, Yusef S, Anderson C, et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004;148:52-61
  • Sleight P. The ONTARGET/TRANSCEND Trial Programme: baseline data. Acta Diabetol 2005;42:S50-6
  • Dieer HC, Sacco R, Yusuf S; Steering Committee and PROFESS Study Group. 1. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes (PROFESS) trial. Cerebrovasc Dis 2007;23:368-80

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.